Tin tức & Cập nhật

Thrombectomy tied to better functional outcomes in large ischaemic stroke patients
Thrombectomy tied to better functional outcomes in large ischaemic stroke patients
01 May 2024
Long-term lecanemab reduces cognitive decline in early AD
Long-term lecanemab reduces cognitive decline in early AD
30 Apr 2024 bởiStephen Padilla

Treatment with lecanemab continue to provide benefits to patients with early Alzheimer’s disease (AD) through 24 months, according to the results of the ongoing open-label extension study of Clarity AD. Those who have been treated much later also show disease improvements.

Long-term lecanemab reduces cognitive decline in early AD
30 Apr 2024
Does BMI affect functional outcomes in stroke patients on rehab?
Does BMI affect functional outcomes in stroke patients on rehab?
30 Apr 2024 bởiStephen Padilla

A study in Singapore provides further evidence regarding the benefits of poststroke rehabilitation in improving function, reducing disability, and discharging patients. In addition, the results show that body mass index (BMI) in any category does not predict the ability to attain functional independence following inpatient rehabilitation.

Does BMI affect functional outcomes in stroke patients on rehab?
30 Apr 2024
New long-term data confirm safety, efficacy of atogepant for migraine prevention
New long-term data confirm safety, efficacy of atogepant for migraine prevention
27 Apr 2024 bởiJairia Dela Cruz

Daily use of the oral calcitonin gene-related peptide (CGRP) receptor antagonist atogepant to prevent migraine is associated with a favourable safety profile and sustained improvements in efficacy outcomes, according to the 52-week data from an ongoing, open-label, 156-week safety extension study.

New long-term data confirm safety, efficacy of atogepant for migraine prevention
27 Apr 2024
Ecopipam cuts Tourette tics
Ecopipam cuts Tourette tics
25 Apr 2024 bởiAudrey Abella

Children and adolescents with Tourette syndrome (TS) may benefit from ecopipam, a first-in-class selective dopamine-1 (D1) receptor antagonist, as it reduced the number of tics and level of daily interference in a post hoc analysis of the phase IIb D1AMOND trial.

Ecopipam cuts Tourette tics
25 Apr 2024